Inhibiting Kiss1 Neurons With Kappa Opioid Receptor Agonists to Treat Polycystic Ovary Syndrome and Vasomotor Symptoms
| Autor: | Eugene Cheung, Susan D. Reed, Daniel Dischino, Rajae Talbi, Elizabeth A. McCarthy, Claudio D. Schteingart, Pierre Riviere, Caroline A Maguire, Robert A. Steiner, Silvia Leon, Víctor M. Navarro |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Agonist
medicine.medical_specialty medicine.drug_class Endocrinology Diabetes and Metabolism Clinical Biochemistry Meloxicam Biochemistry κ-opioid receptor Mice Endocrinology Internal medicine Animals Humans Medicine Online Only Articles Testosterone Neurons Kisspeptins Vasomotor business.industry Receptors Opioid kappa Biochemistry (medical) medicine.disease Polycystic ovary Buprenorphine Vasomotor System Menopause Disease Models Animal Hypothalamus Hot Flashes Female business Polycystic Ovary Syndrome Blood sampling |
| Zdroj: | J Clin Endocrinol Metab |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/clinem/dgab602 |
| Popis: | Context Recent evidence suggests that vasomotor symptoms (VMS) or hot flashes in the postmenopausal reproductive state and polycystic ovary syndrome (PCOS) in the premenopausal reproductive state emanate from the hyperactivity of Kiss1 neurons in the hypothalamic infundibular/arcuate nucleus (KNDy neurons). Objective We demonstrate in 2 murine models simulating menopause and PCOS that a peripherally restricted kappa receptor agonist (PRKA) inhibits hyperactive KNDy neurons (accessible from outside the blood–brain barrier) and impedes their downstream effects. Design Case/control. Setting Academic medical center. Participants Mice. Interventions Administration of peripherally restricted kappa receptor agonists and frequent blood sampling to determine hormone release and body temperature. Main Outcome Measures LH pulse parameters and body temperature. Results First, chronic administration of a PRKA to bilaterally ovariectomized mice with experimentally induced hyperactivity of KNDy neurons reduces the animals’ elevated body temperature, mean plasma LH level, and mean peak LH per pulse. Second, chronic administration of a PRKA to a murine model of PCOS, having elevated plasma testosterone levels and irregular ovarian cycles, suppresses circulating levels of LH and testosterone and restores normal ovarian cyclicity. Conclusion The inhibition of kisspeptin neuronal activity by activation of kappa receptors shows promise as a novel therapeutic approach to treat both VMS and PCOS in humans. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|